{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:17:07Z","timestamp":1778156227666,"version":"3.51.4"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41409-026-02831-2","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T09:03:53Z","timestamp":1774861433000},"page":"639-641","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baseline absolute lymphocyte count, C-reactive protein, and ferritin predict CAR T cell-related toxicities and outcomes in multiple myeloma"],"prefix":"10.1038","volume":"61","author":[{"given":"Darren","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-5978","authenticated-orcid":false,"given":"Tarek H.","family":"Mouhieddine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianxiang","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijia","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Moshier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana C.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larysa J.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Thibaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-5757","authenticated-orcid":false,"given":"Hearn J.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0274-4292","authenticated-orcid":false,"given":"Shambavi","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"2831_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RP, Lu T, Shi V, Bot A, Rossi J, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol. 2017;35:1803\u201313.","journal-title":"J Clin Oncol"},{"key":"2831_CR2","doi-asserted-by":"publisher","first-page":"12778","DOI":"10.1182\/blood-2022-158080","volume":"140","author":"DK Hansen","year":"2022","unstructured":"Hansen DK, Peres LC, Freeman CL, Castaneda Puglianini OA, Faramand R, Oswald LB, et al. Baseline systemic inflammatory markers interleukin 6 and ferritin are associated with toxicities and progression-free survival in multiple myeloma patients treated with idecabtagene vicleucel. Blood. 2022;140:12778\u201380.","journal-title":"Blood"},{"key":"2831_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen AD, Parekh S, Santomasso BD, G\u00e1llego P\u00e9rez-Larraya J, van de Donk NW, Arnulf B, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood cancer J. 2022;12:32.","journal-title":"Blood cancer J"},{"key":"2831_CR4","first-page":"S202","volume":"31","author":"KJC Lim","year":"2025","unstructured":"Lim KJC, Chhabra S, Corraes ADMS, Parrondo RD, Gertz M, Hwa L, et al. Risk Factors for Delayed Neurotoxicity in Patients with Relapsed Myeloma Who Received Ciltacabtagene Autoleucel (cilta-cel). Transpl Cell Ther, Publ Am Soc Transpl Cell Ther. 2025;31:S202.","journal-title":"Transpl Cell Ther, Publ Am Soc Transpl Cell Ther"},{"key":"2831_CR5","doi-asserted-by":"crossref","unstructured":"Mejia Saldarriaga M, Pan D, Unkenholz C, Mouhieddine TH, Velez-Hernandez JE, Engles K, et al. Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma. Blood Adv. 2024. bloodadvances. 2023012470","DOI":"10.1182\/bloodadvances.2023012470"},{"key":"2831_CR6","first-page":"S215","volume":"31","author":"J Turner","year":"2025","unstructured":"Turner J, Forsberg PA, Nicholson S, Schade H, Matous J, Gregory TK. Prophylactic dexamethasone rescues unrestrained lymphocyte expansion in anti-BCMA chimeric antigen receptor T cell therapy in multiple Myeloma. Transpl Cell Ther, Publ Am Soc Transpl Cell Ther. 2025;31:S215\u2013S6.","journal-title":"Transpl Cell Ther, Publ Am Soc Transpl Cell Ther"},{"key":"2831_CR7","first-page":"283. e1","volume":"30","author":"OS Akhtar","year":"2024","unstructured":"Akhtar OS, Modi K, Kim J, Skelson L, Smith E, Al-Jumayli MA, et al. Simple score of albumin and CRP predicts high-grade toxicity in patients with multiple myeloma receiving CAR-T therapy. Transpl Cell Ther. 2024;30:283. e1\u2013. e10.","journal-title":"Transpl Cell Ther"},{"key":"2831_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1169071","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu Y, Jie X, Wang Y, Wu Q, Qiao J, Chen W, et al. A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed\/refractory multiple myeloma patients treated with CAR-T cells. Front Immunol. 2023;14:1169071.","journal-title":"Front Immunol"},{"key":"2831_CR9","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1200\/JCO.23.02232","volume":"42","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, et al. Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42:1665\u201375.","journal-title":"J Clin Oncol"},{"key":"2831_CR10","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1084\/jem.20091474","volume":"207","author":"LE Sander","year":"2010","unstructured":"Sander LE, Sackett SD, Dierssen U, Beraza N, Linke RP, M\u00fcller M, et al. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med. 2010;207:1453\u201364.","journal-title":"J Exp Med"},{"key":"2831_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34560-7","volume":"13","author":"J Jia","year":"2022","unstructured":"Jia J, Wang M, Meng J, Ma Y, Wang Y, Miao N, et al. Ferritin triggers neutrophil extracellular trap-mediated cytokine storm through Msr1 contributing to adult-onset Still\u2019s disease pathogenesis. Nat Commun. 2022;13:6804.","journal-title":"Nat Commun"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02831-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02831-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02831-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:50:31Z","timestamp":1778154631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02831-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2831"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02831-2","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DP: Research funding from Johnson & Johnson, and consulting activity for Regeneron, Pfizer, and Johnson & Johnson. THM: Advisory board fees for Sanofi. JR: Consultant\/advisory board: Janssen, BMS, Pfizer, Karyopharm, Sanofi, Takeda, Genentech, Abbvie, Regeneron, Forus, Menarini, Speakers Bureau: Janssen, BMS, Sanofi, Adaptive Biotechnologies. SP: Consulting: Genentech\/Roche, Poseida Therapeutics, AstraZeneca, Karyopharm, Bristol Myers Squibb, Janssen\/Johnson & Johnson, advisory board for Grail; research support from Celgene\/BMS Corporation, Grail, Caribou, imCORE\/Genentech, Janssen\/Johnson & Johnson. SJ: Consulting for Janssen Pharmaceuticals, BMS, Caribou Biosciences, Legend Biotech, Regeneron Pharmaceuticals, Takeda Pharmaceuticals, Sanofi, Poseida Therapeutics; Advisory board for Janssen Pharmaceuticals, BMS, GSK; Data Safety Monitoring Board for Janssen Pharmaceuticals, Sanofi, Genmab. A. Chari has received research funding from Janssen, and he reported consulting activity for Abbvie, Adaptive, Amgen, Antengene, Bristol Myers Squibb, Forus, Genentech\/Roche, Glaxo Smith Klein, Janssen, Karyopharm, Millenium\/Takeda, and Sanofi\/Genzyme. ACR: Consulting for Johnson & Johnson, Adaptive, BMS, Sanofi. LJS: Consulting\/advisory board for Janssen Pharmaceuticals. CR: Advisory board for Janssen Pharmaceuticals, Takeda Pharmaceuticals, BMS, Amgen, Karyopharm Therapeutics. HJC: Employment: The Multiple Myeloma Research Foundation, Research funding: Genentech\/Roche, BMS, Takeda. The remaining authors declare no relevant competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}